# Selank Half Life and Pharmacokinetics: What Is and Isn't Known

> Selank half life: the intact heptapeptide is short-lived (minutes), with active metabolites proposed to extend its effect. Human pharmacokinetics are poorly characterized — stated honestly, cited.

What the literature supports about duration — and where it goes quiet.

## The short version

The Selank half life question has a two-part answer. The peptide itself does not last long in the body — the intact molecule is cleared in a matter of minutes, which is normal for small peptides. But its breakdown products (metabolites) are thought to stay active, which would stretch out how long an effect lasts beyond what the parent molecule's quick clearance suggests. That fits what users describe: a noticeable per-dose effect of a few hours rather than a few minutes. The honest gap, stated plainly: there is no rigorous, validated human pharmacokinetic study of Selank in mainstream Western literature, so precise numbers should be treated with caution. Selank is not FDA-approved, and nothing here is dosing guidance.

## The intact peptide is short-lived

Selank itself is rapidly metabolized. The reported plasma half-life of the intact heptapeptide is on the order of minutes — commonly cited as a few minutes — which is typical for a small, proline-containing peptide exposed to plasma peptidases. This short parent half-life is precisely the problem the molecule's design addresses: the C-terminal Pro-Gly-Pro extension was added to tuftsin specifically to slow enzymatic degradation relative to the native tetrapeptide [2]. In other words, Selank is already the stabilized version, and even so the intact molecule does not persist long in circulation.

## Active metabolites and functional duration

The leading explanation for why a short-lived peptide produces a longer-feeling effect is metabolite activity. The metabolites of Selank are proposed to retain biological activity, which would extend the functional duration of effect well beyond the parent compound's plasma half-life. This is mechanistically plausible — proline-rich peptides commonly yield active fragments — but it is not rigorously quantified in mainstream Western sources, and it should be read as a reasoned hypothesis supported by the design rationale rather than as a settled pharmacokinetic fact.

## Route matters for duration of effect

Because the intact peptide clears quickly, the route of administration shapes the practical duration and onset reported in studies and by users. The intranasal route is the primary clinical route in Russia [6], and a mouse comparison found that intranasal administration produced central pharmacological effects comparable to systemic dosing [12]. Community reports of a noticeable onset within roughly 20 to 40 minutes intranasally, and a per-dose effect lasting a few hours, are consistent with a short-lived parent peptide acting partly through metabolites — though, as flagged on [Selank effects](/effects), those timing reports are anecdotal.

## The pharmacokinetic data gap

Here the record is genuinely thin, and this site says so. Pharmacokinetics of intact Selank in humans are poorly characterized in mainstream literature, and no rigorously validated human PK profile is published in mainstream Western sources [6]. The "active metabolite" account of a prolonged effect is plausible but not rigorously quantified [6]. Anyone citing a specific Selank half life figure should treat it as approximate and provisional. The honest position is that the parent peptide is short-lived, metabolites likely matter, and the precise human numbers are not established — a gap, not a settled value.

---

A verification-minded reading of the Selank record — the GABA, enkephalinase and monoamine findings logged to source and tagged by evidence strength, the single-region Russian base and unknown human pharmacokinetics named without flinching; no clinic behind the console, and nothing here dispensed or sold.